European Society for Medical Oncology (ESMO) Congress 2021
16 September 2021 - 21 September 2021
6 months of adjuvant trastuzumab noninferior to 12 months in HER2-positive early breast cancer
Six months of adjuvant trastuzumab treatment is noninferior to the standard of care (SoC) of 12 months in patients with HER2-positive early-stage breast cancer, according to results from an individual patient data (IPD) meta-analysis of five noninferiority randomized controlled trials (RCTs) presented at the European Society for Medical Oncology (ESMO) Congress 2021.
6 months of adjuvant trastuzumab noninferior to 12 months in HER2-positive early breast cancer
23 Nov 2021
Pembrolizumab extends RFS in stage II melanoma
Pembrolizumab extended recurrence-free survival (RFS) in patients with high-risk stage II melanoma who had undergone complete resection, interim analysis results of the phase III KEYNOTE-716 trial showed.
Pembrolizumab extends RFS in stage II melanoma
01 Nov 2021
KEYNOTE unlocks immunotherapy OS benefit in metastatic TNBC, effective in early disease
Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of breast cancer and has a dismal prognosis. However, immunotherapy survival benefits reported in KEYNOTE-522 and KEYNOTE-355 trials bring new hope for this indication. [Ann Oncol 2021;32:994-1004]
KEYNOTE unlocks immunotherapy OS benefit in metastatic TNBC, effective in early disease
14 Oct 2021
ADT-docetaxel-abiraterone: A winning combo for mCSPC
Triplet therapy combining androgen deprivation therapy (ADT), docetaxel, and abiraterone-prednisone improves overall survival (OS) in men with de novo metastatic castration-sensitive prostate cancer (mCSPC), according to results of the phase III PEACE-1 trial presented at ESMO 2021.
ADT-docetaxel-abiraterone: A winning combo for mCSPC
07 Oct 2021
Palbociclib plus letrozole prolongs survival in Asian patients with advanced breast cancer
Palbociclib plus letrozole as first-line treatment improves progression-free survival (PFS) vs placebo plus letrozole in postmenopausal Asian patients with advanced oestrogen receptor (ER)–positive and HER2-negative breast cancer (BC), primary results of the phase III PALOMA-4 study have shown.
Palbociclib plus letrozole prolongs survival in Asian patients with advanced breast cancer
29 Sep 2021
Olanzapine a favourable alternative to dexamethasone for CINV
Olanzapine administered at a dose of 5 mg was noninferior to dexamethasone and is associated with fewer adverse effects than dexamethasone for chemotherapy-induced nausea and vomiting (CINV), according to data presented at ESMO 2021.
Olanzapine a favourable alternative to dexamethasone for CINV
27 Sep 2021
Ribociclib plus letrozole improves OS in hormone receptor–positive, HER2-negative advanced breast cancer
A combined regimen of ribociclib plus letrozole as first-line treatment provides a statistically significant and clinically meaningful overall survival (OS) benefit vs placebo plus letrozole in postmenopausal patients with hormone receptor–positive and HER2-negative advanced breast cancer (BC), results of the phase III MONALEESA-2 study have shown.
